Oaxaca Site Management Organization S.C. | Oaxaca, Mexico

Research site

(Unclaimed)

Location

Humboldt 302 centro, Oaxaca, Oaxaca, Mexico

Site insights

Top conditions

Top treatments

Pembrolizumab

Avelumab

MK-4482

Sunitinib

Ibrutinib

Fulvestrant

Ritonavir

Olaparib

PF-05280014

Trastuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 25 total trials

(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling

Metastatic Cancer

Advanced Gastrointestinal Stromal Tumors

Drug: CGT9486 plus sunitinib

Drug: CGT9486

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to i...

Enrolling

Waldenstrom Macroglobulinemia

Follicular Lymphoma

Drug: Ibrutinib

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling

NASH - Nonalcoholic Steatohepatitis

Drug: Placebo

Drug: IVA337

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population wit...

Active, not recruiting

Head and Neck Squamous Cell Carcinoma

Drug: Lenvatinib

Drug: Placebo

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC)

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult pa...

Active, not recruiting

Breast Cancer

Locally Advanced Breast Cancer

Drug: Samuraciclib

Drug: Fulvestrant

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV)...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: Cisplatin

Radiation: Hypo-fractioned radiation therapy

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

The primary objective of this study is to evaluate the efficacy of Debio 4326 in suppressing serum luteinizing hormone (LH) to prepubertal levels 52...

Enrolling

Central Precocious Puberty

Drug: Debio 4326

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Enrolling

Advanced or Metastatic Breast Cancer

Drug: Everolimus

Drug: Fulvestrant

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall s...

Active, not recruiting

Advanced Malignancies

Urothelial Cancer

Drug: Utomilumab

Drug: Axitinib

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectab...

Active, not recruiting

Advanced Solid Neoplasms

Drug: Olaparib

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling

Arteriosclerosis

Hypercholesterolaemia

Drug: Placebo

Drug: Enlicitide Decanoate

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10)

This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic...

Active, not recruiting

Squamous Non Small Cell Lung Cancer

Nonsquamous Non Small Cell Lung Cancer

Drug: Pembrolizumab

Drug: Pemetrexed